. Author manuscript; available in PMC: 2019 Apr 1.

Published in final edited form as: Circ Genom Precis Med. 2018 Apr;11(4):e001854. doi: 10.1161/CIRCGEN.117.001854

Table 2.

Genome-wide association results for baseline PRA among PEAR white participants and prioritization with respect to atenolol or HCTZ BP response

SNP	CHR	Location	Nearest gene region	#SNPs in region	A1	Freq A1	Baseline log PRA		SBP Response		DBP Response
SNP	CHR	Location	Nearest gene region	#SNPs in region	A1	Freq A1	β (SE)	P-value	β (SE)	P-value^*	β (SE)	P-value^*
Validation through Atenolol BP Response									Atenolol BP Response
rs7184292	16	51,477,067	CHD9	2	A	0.42	0.30 (0.05)	4.05E-09	−1.68 (0.78)	0.015	−0.61 (0.51)	0.113
Validation through HCTZ BP Response									HCTZ BP Response
rs3784921	16	11,681,702	SNN-TXNDC11	3	G	0.93	0.47 (0.10)	2.09E-06	2.97 (1.19)	0.006	1.94 (0.82)	0.009

P-value is one-sided, based on the one-sided prioritization hypothesis

SNP: Single nucleotide polymorphism; CHR: Chromosome; Location based on NCBI build 36; A1: Reference Allele; HCTZ: hydrochlorothiazide; BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure; PRA: plasma renin activity; PEAR: Pharmacogenomic Evaluation of Antihypertensive Responses

N=461 (Baseline PRA), N=233 (Atenolol BP response), N=228 (HCTZ BP response)